Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
945results about How to "Shorten the progress" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Methods and devices for renal nerve blocking
InactiveUS6978174B2Shorten the progressResolution of overloadPharmaceutical delivery mechanismImplantable neurostimulatorsDiseaseNephropathy
A method and apparatus for treatment of cardiac and renal diseases associated with the elevated sympathetic renal nerve activity by implanting a device to block the renal nerve signals to and from the kidney. The device can be a drug pump eluting implant for targeted delivery of a nerve-blocking agent to the periarterial space of the renal artery.
Owner:MEDTRONIC ARDIAN LUXEMBOURG SARL
Biphenyl-pyrazolecarboxamide compounds
The present invention relates to biphenyl-pyrazole compounds and in particular biphenyl-pyrazolecarboxamides. The invention further provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by antagonism or inverse agonism of the CB1 receptor, such as obesity, smoking cessation, and normalization of blood lipid composition.
Owner:SUN PHARMA IND INC
Methods and apparatuses for altering relative curvature of field and positions of peripheral, off-axis focal positions
ActiveUS7025460B2Shorten the progressLow elongationSpectales/gogglesEye diagnosticsOphthalmologyFocal position
Owner:THE VISION CRC LTD
Immunotherapy for clearing pathological tau conformers
ActiveUS20080050383A1Promote clearanceSlow progressionNervous disorderPeptide/protein ingredientsImmunotherapyImmunogenicity
The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tangle-related behavioral phenotype in a subject.
Owner:NEW YORK UNIVERSITY
Method of treating macular degeneration with a prostaglandin derivative
InactiveUS6225348B1Reduce elevated intraocular pressureReduce morbidityBiocideElcosanoid active ingredientsProstaglandin F2alphaProstaglandin PGE
A method of treating age-related macular degeneration in an eye is described, comprising contacting the eye with a therapeutic amount of a prostaglandin F2alpha derivative. The preferred prostaglandin F2alpha derivative is latanoprost, and the preferred dosage is between about 1.5 mug and about 4.5 mug per day per eye.
Owner:PAULSEN ALFRED W
Shape memory devices and methods for reshaping heart anatomy
InactiveUS20060015002A1Improve shrinkageReduce widthSuture equipmentsSurgical needlesCardiac surfaceHeart anatomy
Systems, methods and devices are provided for treating heart failure patients suffering from various levels of heart dilation. Such heart dilation is treated by reshaping the heart anatomy with the use of shape memory elements. Such reshaping changes the geometry of portions of the heart, particularly the right or left ventricles, to increase contractibility of the ventricles thereby increasing the stroke volume which in turn increases the cardiac output of the heart. The shape memory elements have an original shape and at least one memory shape. The elements are implanted within the heart tissue or attached externally and / or internally to a surface of the heart when in the original shape. The elements are then activated to transition from the original shape to one of the at least one memory shapes. Transitioning of the elements cause the associated heart tissue areas to readjust position, such as to decrease the width of the ventricles. Such repositioning is maintained over time by the elements, allowing the damaging effects of heart dilation to slow in progression or reverse.
Owner:MICARDIA CORP
Use of TNFalpha inhibitor for treatment of erosive polyarthritis
ActiveUS20070071747A1Lost timeSafe and effective meanCompounds screening/testingOrganic active ingredientsAntigen bindingPolyarthritis
The invention describes methods of treating erosive polyarthritis comprising administering a TNFα antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNFα antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
Owner:ABBVIE BIOTECHNOLOGY LTD
Methods and systems for cardiac remodeling via resynchronization
InactiveUS7877142B2Improve shrinkageReduce widthHeart stimulatorsProsthesisElectricityExternal pacemakers
Systems, methods and devices are provided for improving the hemodynamic efficiency of a patient's heart by implanting one or more reinforcement elements on or with the heart and providing electrical stimulation to the heart. The reinforcement elements may include magnetic and / or shape memory material and are configured to reshape the heart so as to boost the heart's mechanical energy during a response to the electrical stimulation. In some embodiments, at least one reinforcement element includes an electrode configured to sense electrocardiogram signals within the heart. An electrical stimulation device such as an implantable or external pacemaker / defibrillator may be configured to control delivery of electrical pulses to the heart based on the sensed electrocardiogram signals. In addition, or in other embodiments, at least one reinforcement element includes an electrode configured to deliver the electrical pulses to the heart.
Owner:MICARDIA CORP
Immunological targeting of pathological tau proteins
ActiveUS20100316564A1Promote clearanceSlow progressionNervous disorderMuscular disorderPeptideImmunogenicity
The present invention relates to methods and compositions for treating, preventing, and diagnosing Alzheimer's Disease or other tauopathies in a subject by administering an immunogenic tau peptide or an antibody recognizing the immunogenic tau epitope under conditions effective to treat, prevent, or diagnose Alzheimer's Disease or other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tau-pathology related behavioral phenotype in a subject.
Owner:NEW YORK UNIVERSITY
Extra-Articular Implantable Mechanical Energy Absorbing Systems
ActiveUS20080275555A1Easy to detectEasy to replaceSuture equipmentsInternal osteosythesisExtra-ArticularMechanical energy
Owner:MOXIMED INC
Methods and apparatuses for altering relative curvature of field and positions of peripheral, off-axis focal positions
ActiveUS20050105047A1Improve acuityRetarding and eliminating progressionSpectales/gogglesEye diagnosticsFocal positionOptical aberration
A method and apparatus are disclosed for controlling optical aberrations to alter relative curvature of field by providing ocular apparatuses, systems and methods comprising a predetermined corrective factor to produce at least one substantially corrective stimulus for repositioning peripheral, off-axis, focal points relative to the central, on-axis or axial focal point while maintaining the positioning of the central, on-axis or axial focal point on the retina. The invention will be used to provide continuous, useful clear visual images while simultaneously retarding or abating the progression of myopia or hypermetropia.
Owner:THE VISION CRC LTD
Shape memory devices and methods for reshaping heart anatomy
InactiveUS7285087B2Improve shrinkageReduce widthSuture equipmentsSurgical needlesCardiac surfaceHeart Part
Owner:MICARDIA CORP
Methods for inhibiting protein kinases
InactiveUS20070082900A1Shorten the progressBiocideOrganic active ingredientsPim kinasesMolecular biology
The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim kinases, and tyrosine kinase using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with protein kinases using such compounds.
Owner:SCHERING CORP
Methods and apparatuses for altering relative curvature of field and positions of peripheral, off-axis focal positions
ActiveUS20070115431A1Good central visionPrevent initiationSpectales/gogglesLaser surgeryPhysicsFocal position
A method and apparatus are disclosed for controlling optical aberrations to alter relative curvature of field by providing ocular apparatuses, systems and methods comprising a predetermined corrective factor to produce at least one substantially corrective stimulus for repositioning peripheral, off-axis, focal points relative to the central, on-axis or axial focal point while maintaining the positioning of the central, on-axis or axial focal point on the retina. The invention will be used to provide continuous, useful clear visual images while simultaneously retarding or abating the progression of myopia or hypermetropia.
Owner:THE VISION CRC LTD
Anti-cd20 therapeutic compositions and methods
InactiveUS20100330089A1Slow tumor growthEliminate the effects ofNervous disorderAntibody mimetics/scaffoldsAntigenDisease
The present invention provides materials and methods for treatment of diseases involving aberrant B-cell activity, using a CD20-specific binding molecule, in particular, antibodies or antigen binding fragment thereof. The compositions disclosed herein is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases.
Owner:EMERGENT PRODUCTS DEVELOPMENT SEATTLE LLC +1
Means for controlling the progression of myopia
ActiveUS20070296916A1Low elongationInhibit progressSpectales/gogglesOptical partsOptical propertyCentral vision
A contact lens (10) for use in controlling or retarding the progression of myopia in an eye has a central optical zone (20) approximating the normal diameter of the pupil of the eye (22) that gives clear central vision at distance for the wearer. An annular peripheral optical zone 24 that is substantially outside the diameter of the pupil is formed around the central optical zone (20) with greater refractive power than that of the central zone (22) so that oblique rays entering the eye through the peripheral optical zone (24) will be brought to focus at a focal plane that is substantially on or anterior to the peripheral region of the retina. Preferably, the rear surface (16) of the lens is shaped to conform to the cornea of the eye and the front surface (18) of the lens (10) is shaped to provide—in conjunction with the rear surface (16)—the desired optical properties of the central and peripheral optical zones. The front surface (18) is also preferably contoured to form a smooth transition (30) between the junction of the central optical zone (20) and the peripheral optical zone (24), with or without designed optical properties such as progressive power.
Owner:THE VISION CRC LTD
Methods and apparatuses for altering relative curvature of field and positions of peripheral, off-axis focal positions
ActiveUS7503655B2Shorten the progressLow elongationSpectales/gogglesLaser surgeryFocal positionOptical aberration
A method and apparatus are disclosed for controlling optical aberrations to alter relative curvature of field by providing ocular apparatuses, systems and methods comprising a predetermined corrective factor to produce at least one substantially corrective stimulus for repositioning peripheral, off-axis, focal points relative to the central, on-axis or axial focal point while maintaining the positioning of the central, on-axis or axial focal point on the retina. The invention will be used to provide continuous, useful clear visual images while simultaneously retarding or abating the progression of myopia or hypermetropia.
Owner:THE VISION CRC LTD
Controlled Delivery of TLR Agonists in Structural Polymeric Devices
ActiveUS20130202707A1Increase successStimulate immune responsePowder deliveryOrganic active ingredientsTlr agonistsDendritic cell
The present invention comprises compositions, methods, and devices for creating an stimulating an antigen-specific dendritic cell immune response. Devices and methods provide prophylactic and therapeutic immunity to subjects against cancer and infectious agents.
Owner:DANA FARBER CANCER INST INC +1
Tau fragments for immunotherapy
The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tangle-related behavioral phenotype in a subject.
Owner:NEW YORK UNIV
Growth factor for hair and skin treatment
InactiveUS20070224150A1Reduce sun exposureShorten the progressCosmetic preparationsHair cosmeticsGlycoproteinPeptide
The present invention relates to a method of treatment for slowing the progress of skin aging comprising contacting the skin with an amount effective to slow skin aging of a composition comprising one or more compounds selected from the group consisting of EGF, bFGF, IGF-1, KGF, TGF-β3, TRX, VEGF, TRX, aFGF, FGF-10, copper peptide, acetyl hexapeptide, palmitoyl pentapeptide, CPP, and UDN glycoprotein.
Owner:CAREGEN
Media file on-demand method, system and appartus
InactiveUS20110055881A1Shorten the progressImprove user experiencePulse modulation television signal transmissionTwo-way working systemsOn demandMedia on demand
The present invention discloses a media file on-demand method, comprising: the server, upon receiving the media on-demand request from the client, provides the index information in the self-defining media file to the client; the server, upon receiving the playing progress request from said client, according to the requested time in the playing progress request, searches for the starting offset position of the media data corresponding to the requested time in the index information; the server, according to the starting offset position of the media data, reads out the media data corresponding to the requested time in the self-defining media file, and provides the media data to the client. The present invention further discloses a media file on-demand system and apparatus, wherein the index information derived by analyzing the original media file divides the original media file into individual segments according to time, thus the user, upon watching the program and dragging on the progress bar, is enabled to request the data according to the time so as to quickly acquire the media data at the time corresponding to the drag-and-drop position, so the experience of use by the user is enhanced.
Owner:TENCENT TECH (SHENZHEN) CO LTD
Distributed symmetric multiprocessing computing architecture
ActiveUS20110125974A1Shorten the progressMemory adressing/allocation/relocationDigital computer detailsSupercomputerGlobal address space
Example embodiments of the present invention includes systems and methods for implementing a scalable symmetric multiprocessing (shared memory) computer architecture using a network of homogeneous multi-core servers. The level of processor and memory performance achieved is suitable for running applications that currently require cache coherent shared memory mainframes and supercomputers. The architecture combines new operating system extensions with a high-speed network that supports remote direct memory access to achieve an effective global distributed shared memory. A distributed thread model allows a process running in a head node to fork threads in other (worker) nodes that run in the same global address space. Thread synchronization is supported by a distributed mutex implementation. A transactional memory model allows a multi-threaded program to maintain global memory page consistency across the distributed architecture. A distributed file access implementation supports non-contentious file I / O for threads. These and other functions provide a symmetric multiprocessing programming model consistent with standards such as Portable Operating System Interface for Unix (POSIX).
Owner:ANDERSON RICHARD S
Method of delaying the onset of clinically definite multiple sclerosis
A method for delaying the onset of clinically definite multiple sclerosis in a patient at risk of developing clinically definite multiple sclerosis and retard long-term progression of multiple sclerosis and its symptoms, the method comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate to the patient, thereby delaying onset of clinically definite multiple sclerosis in the patient and retarding long-term progression of multiple sclerosis and its symptoms.
Owner:YEDA RES & DEV CO LTD
Contact lens and method
ActiveUS7832859B2Delay myopia progressionShorten the progressSpectales/gogglesOptical partsContact lens tintVisual acuity
Owner:AUCKLAND UNISERVICES LTD
Continuous Cell Programming Devices
ActiveUS20120100182A1Easy to controlClinical effectiveness of has been limitedOrganic active ingredientsPeptide/protein ingredientsDendritic cellProtective immunity
The present invention comprises compositions, methods and devices for creating an infection-mimicking environment within a polymer scaffold to stimulate antigen-specific dendritic cell activation. Devices of the present invention are used to provide protective immunity to subjects against infection and cancer.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE +1
Substituted-pent-4-ynoic acids
InactiveUS6037367AImprove the level ofSuppressing inappropriate activationBiocideOrganic chemistryMethyl groupCarbon atom
PCT No. PCT / US96 / 11613 Sec. 371 Date Sep. 14, 1998 Sec. 102(e) Date Sep. 14, 1998 PCT Filed Jul. 12, 1996 PCT Pub. No. WO97 / 03945 PCT Pub. Date Feb. 6, 1997Compounds of formula (I) wherein: R1 is -(CR4R5)nC(O)O(CR4R5)mR6, -(CR4R5)nC(O)NR4(CR4R5)mR6, (CR4R5)nO(CR4R5)mR6, or -(CR4R5)rR6: W is alkynyl or 2 carbon atoms; R3 is H or R7; Z is C(O)R13, (CH2)0-1C(O)OR13, (CH2)0-1C(O)NR10R13, (CH2)0-1C(R8R8)OR8, -NHC(O)R7, (CH2)0-1NR10R13, NH[C(O)C(O)OR8], CH2NH[C(O)CNR10R13], CH2S(O)qR7, CH[S(O)qR7]2, dithiolane, (tetrazol-5-yl), thiazol-2-yl, [1,2,4]thiadiazol-5-yl, [1,3,4]oxadiazol-2-yl, imidazol-2-yl, oxazol-2-yl, or (3- or 5-oxadiazolyl[1,2,4]; R7 is -(CR4R5)qR11 or C1-6 alkyl wherein the R11 or C1-6 alkyl group is unsubstituted or substituted one or more times by methyl or ethyl unsubstituted or substituted by 1-3 fluorines, -NR8R10, -CO2R8, -O(CH2qR8, -NR8C(O)R8 or R12; or the pharmaceutically acceptable salts thereof.
Owner:SMITHKLINE BECKMAN CORP
Remedy for cardiac failure containing ask1 inhibitor as active ingredient and method for screening the same
InactiveUS20070167386A1Inhibit functional expressionPreventing cardiac failureOrganic active ingredientsPeptide/protein ingredientsManagement of heart failureLeft Ventricle Remodeling
The present invention provides a drug for at least one of prevention and treatment of cardiac failure capable of suppressing cardiac depression and the onset of cardiac failure in ventricular remodeling, and a method for screening the drug. The drug for at least one of prevention and treatment of cardiac failure of the present invention contains a compound that inhibits a functional expression of ASK1 protein in a cardiomyocyte as an active ingredient, and a method for screening a drug for at least one of prevention and treatment of cardiac failure of the present invention includes selecting a medicinal component for at least one of prevention and treatment of cardiac failure from a drug candidate compound by using inhibition of a functional expression of ASK1 protein as an indication. As shown in FIG. 1, if ASK1 protein is removed, for example, the ventricle dilation can be attenuated in ventricular remodeling after myocardial infarction, pressure loading, or the like, which makes it possible to prevent and treat cardiac failure.
Owner:OSAKA INDAL PROMOTION ORG
Ophthalmic lens with an optically non-coaxial zone for myopia control
ActiveUS20190227342A1Slowing and retarding and preventing myopia progressionPrevent and retard progressionSpectales/gogglesEye treatmentOphthalmologyEye lens
The present disclosure relates to ophthalmic devices such as ophthalmic lenses. An ophthalmic device may comprise an ophthalmic lens for at least one of slowing, retarding or preventing myopia progression. The ophthalmic lens may comprise a center zone with a negative power for myopic vision correction; and at least one treatment zone surrounding the center zone, the at least one treatment zone having a power profile comprising an ADD power, the at least one treatment zone having a surface shape comprising a portion of a generally toroidal shape, wherein the at least one treatment zone is arranged as to form a continuous surface with the center zone.
Owner:JOHNSON & JOHNSON VISION CARE INC
Compositions and methods for modulating NH2-terminal Jun Kinase activity
InactiveUS7232897B2Reduce expressionIncrease insulin sensitivityOrganic active ingredientsBiocideDiabetes mellitusKinase
Disclosed herein are compositions and methods used to modulate a NH2-terminal Jun Kinase activity. These compositions and methods can be employed to regulate metabolic disorders associated with, for example, insulin such as diabetes. The reduction in NH2-terminal Jun Kinase activity can lead to the reduction in weight and improve insulin sensitivity.
Owner:HARVARD UNIV
Osteoarthritis treatment and device
ActiveUS8062364B1Decrease painSlow progressionSurgical adhesivesInternal osteosythesisOsteoarthritic cartilageSyringe
A method for treating arthritis of a joint includes identifying a bone lesion in a bone adjacent to the joint; and implanting in the bone a reinforcing member in or adjacent to the bone lesion. A kit for conducting the method includes: (a) at least one reinforcing member having a proximal face adapted to face the joint, a distal face adapted to face away from the joint, and a wedge-shaped edge adapted to pierce bone, wherein the at least one reinforcing member is planar and sterile; and (b) a container adapted to maintain the at least one reinforcing member sterile. Another kit includes: (a) a sterile fluid; (b) a syringe for injecting the fluid into a bone; (c) a curing agent adapted to cure the fluid to polymerize and / or cross-link; and (d) a container adapted to maintain the sterility of contents of the container.
Owner:ZIMMER KNEE CREATIONS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com